Molecular Partners Completes Manufacturing Runs in Bid for Covid-19 Drug
Follow The Hawk on Google News+ FollowAdvertisement

Zurich: Switzerland's Molecular Partners, which is hoping to produce an antiviral drug against COVID-19, said on Monday that it had completed initial manufacturing runs for its candidate MP0420 that it aims to test in humans starting in November.
"It is essential to demonstrate the ability to manufacture and deploy these medicines," said Chief Executive Patrick Amstutz. —Reuters
Also readFSSAI to initiate action against Bisleri over unsafe water sampleGet The Hawk first on Google
Add The Hawk as a preferred source and Google shows you more of our stories in Top Stories. Follow us on Google News too.
Advertisement








